Biocon to host Macquarie's Healthcare Tour plant visit on June 11

0 min read Updated on 09 Jun 2026, 11:03 AM

Reviewed by

Naman SScanX News Team

AI Summary

Biocon Limited will host a plant visit for Macquarie's Healthcare Tour on June 11, 2026, in Bangalore, serving as a group interaction with analysts and institutional investors. The company stated that the schedule is subject to change due to exigencies on the part of investors or the company. The management confirmed that no unpublished price sensitive information (UPSI) will be disclosed during the meeting.

*this image is generated using AI for illustrative purposes only.

Biocon Limited will host a plant visit for Macquarie's Healthcare Tour on June 11, 2026, in Bangalore. The event will serve as a group interaction with analysts and institutional investors. The company stated that the schedule is subject to change due to exigencies on the part of investors or the company.

The management confirmed that no unpublished price sensitive information (UPSI) will be disclosed during the meeting. This disclosure was made to BSE Limited and National Stock Exchange of India Limited pursuant to Regulation 30(6) of the SEBI Listing Regulations.

The event details are as follows:

Date	Event	Type of Interaction	Venue
11-Jun-26	Macquarie's Healthcare Tour – Plant Visit	Group	Bangalore

Rajesh U. Shanoy, Company Secretary and Compliance Officer, signed the intimation on behalf of Biocon Limited. The information is also available on the company's website.

Historical Stock Returns for Biocon

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.42%	-0.53%	+8.99%	+8.07%	+22.61%	+2.50%

What strategic insights might investors gain from the plant visit regarding Biocon's operational efficiency?

How could this interaction influence institutional investor sentiment ahead of Biocon's next earnings report?

What potential market reactions might arise if any unexpected developments are hinted at during the tour?

Read Next Article

Biocon approves CEO appointment and remuneration revisions

2 min read Updated on 09 Jun 2026, 01:19 AM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

AI Summary

Biocon Limited shareholders approved ten resolutions via postal ballot, including the appointment of Shreehas Pradeep Tambe as CEO & MD and remuneration revisions for Kiran Mazumdar-Shaw. The voting, held from May 09 to June 07, 2026, saw 73.56% participation and approved the preferential issuance of equity shares and several director appointments.

*this image is generated using AI for illustrative purposes only.

Biocon Limited shareholders have approved ten resolutions through a postal ballot process, including the revision of remuneration for Executive Chairperson Kiran Mazumdar-Shaw and the appointment of Shreehas Pradeep Tambe as Chief Executive Officer & Managing Director. The voting, conducted via remote e-voting from May 09 to June 07, 2026, also sanctioned the issuance of equity shares on a preferential basis and the appointment of several independent directors. All resolutions received the requisite majority and were deemed passed on June 07, 2026.

The postal ballot notice was sent to members whose names appeared on the register of members as of the cut-off date of May 01, 2026. The company provided a 30-day window for e-voting, commencing on May 09, 2026. A corrigendum to the notice was issued on May 29, 2026, to provide clarifications regarding the preferential issue of equity shares, following advice from the stock exchanges. Shareholders were given the option to modify their votes prior to the deadline, though no such requests were received.

Voting Results

The scrutinizer's report confirmed that 73.56% of the total paid-up equity capital participated in the e-voting process. The resolutions passed with varying degrees of support, with the preferential issue of shares receiving near-unanimous approval at 99.99% of valid votes.

Resolution	Type	Votes in Favour	Votes Against	% of Valid Votes in Favour
Revision of remuneration for Ms. Kiran Mazumdar-Shaw	Special	1,096,787,824	95,571,206	91.98%
Appointment of Mr. Shreehas Pradeep Tambe as CEO & MD	Special	1,125,209,472	67,150,821	94.37%
Issuance of Equity Shares on Preferential Basis	Special	1,192,326,491	33,067	99.99%
Re-appointment of Ms. Rekha Mehrotra Menon as Independent Director	Special	1,191,587,315	772,927	99.94%
Appointment of Mr. Thomas Jason Roberts as Non-Executive Non-Independent Director	Ordinary	1,192,040,746	319,239	99.97%
Appointment of Mr. Rajiv Malik as Independent Director	Special	1,121,480,368	70,849,827	94.06%
Appointment of Mr. Daniel Bradbury as Independent Director	Special	1,095,975,871	96,354,451	91.92%
Appointment of Mr. Peter Baron Piot as Independent Director	Special	1,192,303,396	26,915	99.99%
Appointment of Dr. Arun Suresh Chandavarkar as Independent Director	Special	1,050,404,724	141,955,598	88.09%
Appointment of Ms. Nivruti Rai as Independent Director	Special	1,192,306,910	23,396	99.99%

Key Appointments

The approvals pave the way for significant changes in the company's leadership and board composition. Shreehas Pradeep Tambe is set to take over as Chief Executive Officer & Managing Director. The board will also see the induction of five new independent directors: Rajiv Malik, Daniel Bradbury, Peter Baron Piot, Arun Suresh Chandavarkar, and Nivruti Rai. Additionally, Thomas Jason Roberts was appointed as a Non-Executive Non-Independent Director, and Rekha Mehrotra Menon was re-appointed as an Independent Director.

The scrutinizer, Pradeep Bheemsen Kulkarni of V Sreedharan & Associates, verified the e-voting process and confirmed that the results were declared based on the votes cast up to 5:00 PM on June 07, 2026. The report was submitted to the company on June 08, 2026.

Historical Stock Returns for Biocon